SurVaxM works similarly to oncolytic viral therapy and is a multiple peptide vaccine conjugate that targets survivin, particularly abundant in Grade IV gliomas, through the activation of cytotoxic T-cells that mediate the destruction of GBM cells using direct cell-cell contact or cytokine release [42,43,44]. The gene discussed is BIRC5; the disease is glioma.